Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,629.20
(
0.56%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
108.11
(
-0.13%
)
Bitcoin
67,480.82
(
2.31%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: DewDiligence post# 109531

Friday, 11/26/2010 6:33:31 PM

Friday, November 26, 2010 6:33:31 PM

Post# of 257302

Maybe. On various message boards, several posters have already scored XL184 as a big win for EXEL and a colossal blunder for BMY—all on the basis of some skimpy results on an endpoint that does not even have a formal definition.

You're presumably just referring to the Phase 2 prostate cancer data that was reported. Any comments on the Phase 2 ovarian cancer data that was reported the same day for XL184 (#msg-56880866)?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today